Article Text

Download PDFPDF
Niacin—a case study for the role of event-driven versus surrogate endpoint trials
  1. Michael J Blaha,
  2. Erin D Michos
  1. Department of Medicine/Cardiology, The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland, USA
  1. Correspondence to Dr Michael J Blaha, Department of Medicine/Cardiology, The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Carnegie 565A, JHH, 600 N. Wolfe St., Baltimore, MD 21287, USA; mblaha1{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The modern approach to lipid-lowering therapy is rooted in the event-driven, randomised clinical trial (RCT). From the Lipid Research Clinics Coronary Primary Prevention Trial to the Coronary Drug Project to the modern statin trials, guidelines have traditionally been informed by large RCTs driven by the outcomes that matter most—heart attacks and strokes.1 Based on a wealth of data from such RCTs, statins are now established as first-line drugs for nearly everyone considered to be at high risk of developing atherosclerotic cardiovascular disease (CVD).

Unfortunately, in the current era, large event-driven RCTs have become increasingly hard to conduct.2 The incidence of CVD is declining in developed nations, requiring either very large sample sizes (a problem compounded by the well-documented decline in RCT participation) or a largely international trial population with limited generalisability. Given the known efficacy of statins, new lipid-lowering therapies must be tested as add-ons to statins, limiting their marginal efficacy and again necessitating larger sample sizes. The global economic slowdown has also limited non-pharmaceutical and pharmaceutical funding for large RCTs, particularly for existing therapies.

The imaging-based surrogate endpoint trial was thought to be the solution to this problem.3 If one could document the benefit of a therapy on a highly sensitive atherosclerosis imaging endpoint, the theory states, one might need far fewer patients to prove the efficacy of a drug. While early statin surrogate endpoint studies showed plaque regression in close correlation with event reduction, studies of other drugs have failed to link surrogate endpoint changes to observed clinical benefits. One example was the ARBITER6-HALTS trial, which randomised patients to ezetimibe versus long-acting niacin as add-on therapy.4 This generally well-conducted trial of 363 patients was stopped early on the basis of a reduction in carotid intima-media thickness in the niacin arm. Although published in the …

View Full Text


  • Contributors Both authors have participated in conception and design, or analysis and interpretation of data; drafting the article or revising it critically for important intellectual content and final approval of the version to be published.

  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles